Clinical & Experimental Cardiology
Open Access

Biomimetic Cardiac Patches for Congenital Heart Defect Repair in Neonates

Michael Dubinsky^{* *}Correspondence: Michael Dubinsky, Department of Cardiology, University of Oxford, Oxford, United Kingdom, Email:

Author info »

Description

Congenital Heart Defects (CHDs) are among the most common birth anomalies, affecting nearly 1% of live births worldwide. These structural abnormalities of the heart can range from simple defects, such as atrial septal defects, to complex malformations, including hypoplastic left heart syndrome and tetralogy of Fallot. Early surgical intervention is often required to correct these defects, particularly in neonates, whose small size and underdeveloped tissues present unique surgical challenges. Traditional repair strategies, including autologous pericardial patches, synthetic materials, and donor grafts, have achieved significant clinical success but are limited by issues such as lack of growth potential, risk of calcification, immunogenicity, and mechanical mismatch with native cardiac tissue. In response to these limitations, the field of regenerative medicine has increasingly focused on the development of biomimetic cardiac patches that aim to replicate the structural, mechanical, and biological characteristics of native myocardium to improve outcomes in neonatal CHD repair.

Biomimetic cardiac patches are engineered constructs designed to mimic the native Extracellular Matrix (ECM), support cardiomyocyte survival, and integrate seamlessly with the host tissue. These patches typically combine biocompatible scaffolds with cellular components or bioactive molecules to promote tissue regeneration. The scaffolds can be fabricated from natural materials such as collagen, fibrin, and decellularized cardiac ECM, or from synthetic polymers such as polycaprolactone, polylactic acid, or polyurethane, which offer tunable mechanical properties. The design of these patches prioritizes compliance with the dynamic mechanical environment of the neonatal heart, where cyclical contraction and relaxation generate substantial mechanical forces. Patches that match the elasticity and anisotropic properties of native myocardium are less likely to induce arrhythmias, fibrotic remodeling, or mechanical stress on surrounding tissues, thereby improving long-term cardiac function.

In addition to mechanical properties, the biological functionality of biomimetic cardiac patches is critical for successful repair. Incorporating living cells, such as induced pluripotent stem cellderived cardiomyocytes, mesenchymal stem cells, or endothelial cells, allows the patch to contribute actively to tissue regeneration rather than serving as a passive structural support. These cells can secrete paracrine factors that stimulate angiogenesis, modulate inflammation, and recruit endogenous progenitor cells, promoting integration with the host myocardium. For neonates, whose regenerative capacity is higher than that of adults, these patches offer a unique opportunity to harness innate repair mechanisms while correcting structural abnormalities. Some designs also incorporate growth factors or gene delivery systems that release bioactive signals in a controlled manner, further enhancing tissue regeneration and guiding the maturation of newly formed cardiac tissue.

Another important aspect of biomimetic patch design is the vascularization of the construct. Adequate perfusion is essential for cell survival, particularly in the high-demand environment of the neonatal myocardium. These approaches facilitate rapid anastomosis with the host vasculature upon implantation, reducing ischemic injury and improving the long-term viability of the graft. Additionally, electrical coupling between the patch and native myocardium is a critical factor to prevent arrhythmias and ensure synchronous contraction. Some biomimetic patches incorporate conductive materials, such as carbon nanotubes or gold nanowires, or use aligned nanofibrous scaffolds to guide cardiomyocyte orientation, promoting functional electromechanical integration.

Preclinical studies in animal models have demonstrated the potential of biomimetic cardiac patches for neonatal CHD repair. For example, decellularized ECM patches seeded with stem cells have shown improved cardiac function, reduced fibrosis, and enhanced vascularization compared with acellular or synthetic patches. Similarly, bioengineered patches with aligned nanofiber architecture have promoted the maturation and alignment of cardiomyocytes, resulting in more physiologic contraction patterns. These studies highlight the importance of combining mechanical, biological, and electrical considerations in patch design to achieve optimal outcomes. While these results are promising, translating these technologies to clinical practice requires addressing challenges related to scalability, manufacturing consistency, immune compatibility, and regulatory approval.

One of the most compelling advantages of biomimetic cardiac patches in neonates is their potential for growth. Traditional synthetic patches do not expand with the child, often necessitating repeat surgeries as the patient grows. Biomimetic patches, particularly those incorporating living cells and ECM components, can remodel and grow in concert with the host tissue. This property is particularly valuable in neonates, whose rapid somatic growth can otherwise compromise the long-term durability of conventional repair materials. Achieving a balance between structural integrity and growth potential remains a key design consideration, as the patch must provide immediate mechanical support while allowing gradual remodeling and expansion. Biomimetic cardiac patches represent a promising advancement in the repair of congenital heart defects in neonates. By replicating the mechanical, structural, and biological properties of native myocardium, these patches have the potential to improve surgical outcomes, promote tissue regeneration, and accommodate postnatal growth.

Conclusion

Preclinical studies have demonstrated encouraging results in terms of functional recovery, vascularization, and cellular integration, while ongoing research aims to address challenges related to immunogenicity, manufacturing, and long-term safety. As bioengineering techniques continue to evolve, biomimetic cardiac patches may become an integral part of the therapeutic arsenal for neonatal CHD, offering a regenerative and durable solution that minimizes the need for repeated interventions and enhances the quality of life for affected infants. The convergence of stem cell biology, advanced biomaterials, and precision engineering holds the potential to transform congenital heart defect repair, moving beyond traditional surgical approaches to a future where tissue-engineered constructs provide both structural support and functional regeneration.